Survival
Mesothelioma survival prediction based on a six-gene transcriptomic signature
iScience 2024 September 23 [Link] Kiarash Behrouzfar, Steve E Mutsaers, Wee Loong Chin, Kimberley Patrick, Isaac Trinstern Ng, Fiona J Pixley, Grant Morahan, Richard A Lake, Scott A Fisher Abstract Mesothelioma is a lethal cancer. Despite promising outcomes associated with immunotherapy, durable responses remain restricted to a minority of patients, highlighting the need for improved…
Read MoreThe impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity
EBioMedicine 2024 November [Link] Mégane Willems, Malik Hamaidia, Alexis Fontaine, Mélanie Grégoire, Louise Halkin, Lea Vilanova Mañá, Roxane Terres, Majeed Jamakhani, Sophie Deshayes, Yves Brostaux, Vincent Heinen, Renaud Louis, Bernard Duysinx, Didier Jean, Eric Wasielewski, Arnaud Scherpereel, Christophe Blanquart, Luc Willems Abstract Background: In mesothelioma (MPM), clinical evidence indicates that the absolute eosinophil count negatively…
Read MoreAntigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma
Scientific Reports 2024 October 29 [Link] Kim Lindland, Marion Masitsa Malenge, Ruth Gong Li, Roxanne Wouters, Tina Bjørnlund Bønsdorff, Asta Juzeniene, Srdan M Dragovic Abstract Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of…
Read MoreCharacteristics of long-term survivors with malignant pleural mesothelioma
The Annals of Thoracic Surgery 2024 October 22 [Link] Isabelle Opitz, Olivia Lauk, Raphael Werner, Alessandra Matter, Monika Hebeisen, Bianca Battilana, Hasan Batirel, Harvey Pass, Raja Flores, Andrea Wolf, Marc de Perrot, Mir Alireza Hoda, Walter Klepetko, Thomas Klikovits, Masaki Hashimoto, Seiki Hasegawa, William G Richards, Raphael Bueno Abstract Background: Pleural mesothelioma (PM) is a…
Read MoreStem-like exhausted CD8 T cells in pleural effusions predict improved survival in non-small cell lung cancer (NSCLC) and mesothelioma
Translational Lung Cancer Research 2024 September 30 [Link] Linda Ye, Heeju Ryu, David Granadier, Long T Nguyen, Yannick Simoni, Ian Dick, Tina Firth, Ebony Rouse, Peter Chiang, Y C Gary Lee, Bruce W Robinson, Jenette Creaney, Evan W Newell, Alec J Redwood Abstract Background: Anti-tumor CD8 T cells are important for immunity but can become…
Read MoreEfficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)
Clinical Lung Cancer 2024 December [Link] Diego Enrico, Juan Elias Gomez, Danilo Aguirre, Natalia Soledad Tissera, Florencia Tsou, Carmen Pupareli, Delfina Peralta Tanco, Federico Waisberg, Andrés Rodríguez, Manglio Rizzo, Nicolás Minatta, Picon Rafael, Luis Basbus, Lorena Lupinacci, Diego Kaen, Mauro Ramos, Virginia Bluthgen, Nicolas Castagneris, María Pía Coppola, Alejandra Scocimarro, María Florencia Guerra, Aldo Perfetti,…
Read MoreFractionated low-dose radiotherapy primes the tumor microenvironment for immunotherapy in a murine mesothelioma model
Cancer Immunology, Immunotherapy 2025 January 3 [Link] Rebecca A D’Alonzo, Synat Keam, Suki Gill, Pejman Rowshanfarzad, Anna K Nowak, Martin A Ebert, Alistair M Cook Abstract Combination immune checkpoint inhibitors (nivolumab and ipilimumab) are currently a first-line treatment for mesothelioma; however, not all patients respond. The efficacy of treatment is influenced by the tumor microenvironment.…
Read MoreImmunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
International Journal of Molecular Sciences 2024 October 9 [Link] Lauren Chiec, Debora S Bruno Abstract Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual…
Read MorePhase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and Design
Cancers 2024 October 4 [Link] Giulia Maria Stella, Daniela Lisini, Paolo Pedrazzoli, Giulia Galli, Chandra Bortolotto, Giulio Melloni, Gioacchino D’Ambrosio, Catherine Klersy, Amelia Grosso, Francesca Paino, Stefano Tomaselli, Laura Saracino, Giulio Alessandri, Augusto Pessina, Elena Grignani, Vittorio Rosti, Angelo Guido Corsico, Patrizia Comoli, Francesco Agustoni Abstract Background and rationale. Pleural mesothelioma (PM) is a rare…
Read MoreImpact of T Cell Ratios on Survival in Pleural Mesothelioma: Insights from Tumor Microenvironment Analysis
Cancers 2924 October 8 [Link] Laura V Klotz, Andreas Weigert, Florian Eichhorn, Michael Allgäuer, Thomas Muley, Rajiv Shah, Rajkumar Savai, Martin E Eichhorn, Hauke Winter Abstract Background: Immunotherapy has significantly improved overall survival in patients with pleural mesothelioma, yet this benefit does not extend to those with the epithelioid subtype. Tumor growth is believed to…
Read More